Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$39.06 USD

39.06
373,482

-0.15 (-0.38%)

Updated Oct 17, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sundeep Ganoria headshot

Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

by Sundeep Ganoria

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

by Zacks Equity Research

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

by Zacks Equity Research

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

by Zacks Equity Research

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.

GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

by Zacks Equity Research

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.

Here's Why GSK (GSK) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

by Zacks Equity Research

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.

Biogen's Lupus Candidate Meets Key Goals in Phase III Study

by Zacks Equity Research

The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease

by Zacks Equity Research

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.

Why GSK (GSK) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines

by Zacks Equity Research

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

by Zacks Equity Research

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

by Zacks Equity Research

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

by Zacks Equity Research

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

by Zacks Equity Research

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?

by Zacks Equity Research

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More

by Zacks Equity Research

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal

by Zacks Equity Research

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

by Zacks Equity Research

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

by Zacks Equity Research

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Mark Vickery headshot

Top Stock Reports for Apple, Tesla & NextEra Energy

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA) and NextEra Energy, Inc. (NEE), as well as two micro-cap stocks Investors Title Company (ITIC) and Autoscope Technologies Corporation (AATC).

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

by Zacks Equity Research

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.